Title:ACEi/ ARB and Deaths of COVID-19 Patients
Volume: 18
Issue: 2
Author(s): Gulam Navi Azad and Anoop Kumar*
Affiliation:
- Department of Pharmacology, Delhi Pharmaceutical Sciences & Research University
(DPSRU)-New Delhi, India
Keywords:
COVID-19, Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin-receptor blocker (ARB), mortality, Rev Man 5, odd ratio.
Abstract: The practice of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers
(ACEi/ARB) in COVID-19 hypertensive patients is still an open question for clinicians to answer.
The present study was conducted to find out the association between the use of ACEI/ARB
and the mortality rate of COVID-19 patients. The search was conducted from December 2019 to
October 2020 in PubMed to identify relevant published studies. RevMan 5 was used for the analysis
of the data. The random-effect model was used to calculate the odds ratio. In total, 07 studies
were found to be appropriate, reporting a total of 1,566 subjects. The odds ratio was found to be
0.86 [0.41, 1.81], indicating no association between ACEI/ARB and the mortality rate of COVID-
19 patients. In conclusion, we may suggest continuing the use of ACEi/ARB in COVID-19 patients
till further pieces of evidence are generated.
